This showed a clear trend towards improved survival compared to patients who only received best supportive care after CAR‐T failure. in comparison to patients who only received best supportive care after CAR‐T failure (Supporting Information S1: Figures 2 and 3 ).
← all excerpts
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study.
1
—
—